RECURRENT PLASMA CELL MYELOMA

This early-stage study tests whether adding a lab-modified reovirus (pelareorep) to a standard drug combination (bortezomib, dexamethasone, and pembrolizumab) can safely improve outcomes for people with multiple myeloma that has relapsed or become resistant. About 10 participants…

This study tests a specific timing of chemotherapy drugs (busulfan and fludarabine) before a donor stem cell transplant, followed by cyclophosphamide after the transplant, to treat high-risk blood cancers like leukemia and lymphoma. The goal is to reduce the chance of the transpl…

This early-phase study tests a new treatment for multiple myeloma that has returned or stopped responding to standard therapies. The treatment uses a patient's own immune cells (T cells) that are specially trained to recognize and attack cancer cells carrying a protein called MUC…

This study tests a two-part treatment plan for people with multiple myeloma that has come back or is not responding to therapy. First, patients receive daratumumab, bortezomib, and dexamethasone, then switch to daratumumab, ixazomib, and dexamethasone. The goal is to see if this …

This early-phase study tests the safety and best dose of two drugs—venetoclax and tocilizumab—in people with a specific genetic subtype of multiple myeloma (t(11;14)) that has returned or stopped responding to treatment. The trial includes both African American and non-African Am…

This study tests a combination of three drugs (isatuximab, carfilzomib, and pomalidomide) in adults with multiple myeloma that has come back or is not responding to prior treatments. The goal is to see if this mix can shrink or control the cancer. The trial enrolled 5 participant…

This study measures how often cancer patients experience cachexia (unintentional weight loss and loss of appetite) and the emotional burden on both patients and their primary caregivers. Researchers will track 192 patients and their caregivers at an outpatient supportive care cli…